In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Ashley M WhiteDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.ORCID 0000-0003-1660-7635 Ashley J CraigDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.
Daryl L RichieDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.ORCID 0009-0005-1459-5089 Christa L CorleyDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.
Percell T KendrickDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.ORCID 0009-0002-0274-2561 Kathleen R McNealyDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.
Michael D ScofieldDepartment of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-2330-6999 Cassandra D GipsonDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40508, USA.
Funding
NRSA Training CoreTL1TR001997 · NCATS · UNIVERSITY OF KENTUCKY · PI PENDERGAST, JULIE S, STOOPS, WILLIAM WALTON · 2016 to 2025
$4.2MNeurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawalR01DA058933 · NIDA · UNIVERSITY OF KENTUCKY · PI Cassandra D Gipson-Reichardt, Terry D Hinds · 2023 to 2026
$2.0MNeuroinflammatory and glutamatergic mechanisms of nicotine seekingR01DA046526 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D · 2019 to 2023
$1.9MGlutamergic Mechanisms in Opioid and Cocaine Co-UseR33DA049130 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D, STOOPS, WILLIAM WALTON · 2022 to 2024
$1.9MCholinergic modulation of glutamatergic signaling in nicotine addiction and relapseR21DA044479 · NIDA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI GIPSON-REICHARDT, CASSANDRA D · 2018 to 2019
$461kContributions of Progestins Independently and Interactively with Contraceptive Estrogen to Nicotine UseR21DA055879 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D · 2022 to 2023
$435kGlutamergic Mechanisms in Opioid and Cocaine Co-UseR21DA049130 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D, STOOPS, WILLIAM WALTON · 2020 to 2021
$402kNeuroimmune and Cognitive Consequences of Nicotine Use in a Rodent Model of HIV: Implications for Anti-Retroviral TherapiesR03DA061626 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D · 2024 to 2025
$324kNCATS NIH HHS TL1 TR001997NIDA NIH HHS DA046526NIDA NIH HHS DA061626NIDA NIH HHS R01 DA046526NIDA NIH HHS R01 DA058933NIDA NIH HHS R03 DA061626NIDA NIH HHS R21 DA044479NIDA NIH HHS R21 DA049130NIDA NIH HHS R21 DA055879NIDA NIH HHS R33 DA049130
6 · The paper itselfAbstract
Smoking remains a leading preventable cause of death, and nicotine is the primary substance responsible for maintaining use of tobacco products. Preclinical rodent models have shown that neuroimmune signaling is dysregulated by nicotine self-administration (SA) within the nucleus accumbens core (NAcore). Microglia are the resident brain immune cell and prior studies have shown that they play an important role in nicotine-related behaviors. However, while transgenic mouse lines allow for specific evaluations of microglia to determine their role in neurobiology and behavior, there are fewer tools available for rats as a model species, thus limiting our ability to evaluate specific contributions of microglia to nicotine SA. A transgenic rat expressing Cre under the control of the CX3CR1 promoter bred on a Long-Evans (LE) background was recently developed, and here we show that NAcore microglia can be virally transduced with designer receptors exclusively activated by designer drugs (DREADDs) without neuronal expression. We further show that CX3CR1::ERT2 rats readily self-administer nicotine and display a characteristic extinction curve. Together, these validation studies lay the foundation for future use of this transgenic rat line to evaluate the specific contributions of microglia within the brain reward pathway to the neurobehavioral underpinnings of nicotine addiction.
Indexed as
CX3C Chemokine Receptor 1IntegrasesNicotineAnimalsMaleMicrogliaNucleus AccumbensRatsRats, Long-EvansRats, TransgenicSelf AdministrationCre recombinaseCX3C Chemokine Receptor 1CX3CR1 protein, ratIntegrasesNicotinebehaviorDREADDsmicroglianicotineself-administration
Identifiers
PMID42645173
PMCPMC13511460
What Socratic holds
Textmetadata
Read underepoch 390